50mg vial ghk cu GHK-Cu GHK-CU — ≥99% Purity, COA

What the FDA Has Said About BPC-157 and Compounding In September 2023, the FDA put BPC-157 in Category 2 of the 503A Interim Bulks Guidance, which stopped pharmacies from compounding it

Every treatment is customized to your recovery timeline, not a generic protocol

Despite the massive surge in public excitement and the celebratory press releases issued by wellness clinics following the HHS Secretarys podcast announcement, specialized regulatory attorneys and legal experts have issued stark, sobering warnings to the medical community

Y.Yokota-HashimotoH.TaguchiR.et al (2014)

Blood-brain-barrier-penetrant AngIV analog Studied as a metabolically stabilized, orally active angiotensin-IV derivative designed to reach the brain in animal pharmacokinetic work

What is missing is the human half of the story: no clinical trials, no long-term safety record, and an oral route that makes sense but has not been measured in people